Sungkyunkwan University · Medicine
Professor Yeon Hee Park's research lab specializes in translational breast cancer genomics, focusing on understanding the molecular and immune dynamics of treatment response and resistance in HER2-positive and triple-negative breast cancers. The lab integrates multi-omics approaches—such as whole exome sequencing, transcriptome profiling, and immunohistochemistry—across longitudinal patient cohorts to identify predictive biomarkers and therapeutic vulnerabilities. Key research directions include the impact of neoadjuvant chemotherapy on the tumor immune microenvironment, the clinical relevance of tumor mutational burden in metastatic disease, and the development of targeted therapies for treatment-experienced patients. The lab also actively contributes to clinical trial design and biomarker discovery in precision oncology.
Figures are computed from collected data and may differ slightly.
To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcriptome profiling coupled with histopathology analyses of a longitudinal breast cancer cohort of 146 patients including 110 pairs of serial tumor biopsies collected before treatment, after the first cycle of treatment and at the time of surgery. Here, we show that cytotoxic chemotherapies induce dynamic changes in the tumor immune microenvironment that vary by subtype and pathologic response. Just one cycle of tre
This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient population who had been previously treated but had subsequent disease progression. Whole exome sequencing was performed on formalin-fixed paraffin-embedded tumor samples and matched normal tissue. Among the 46 patients, 13 (28.3%) were estrogen receptor-positive and nine (19.6%) were progesterone receptor-positive by immunohistochemistry analysis.
ClinicalTrials.gov, NCT03401359. The trial was posted on 18 January 2018 and registered prospectively.
Although the introduction of human epidermal growth factor receptor (HER)2-directed therapy including trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancers (mBCs) favorably changed the natural history of this disease, most cases of HER2-positive mBC will eventually progress. Poziotinib is an oral pan-HER kinase inhibitor showing potent activity through irreversible inhibition of these kinases. This open-label, multicenter
ClinicalTrials.gov Identifier: NCT03881878.
Open papers in the app to read, cite, and organize with AI.
